ChiCTR2000032726 版本V1.4 版本创建时间2020/05/09 01:30:35 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000032726 

最近更新日期:

Date of Last Refreshed on:

2020-05-09 01:23:24 

注册时间:

Date of Registration:

2020-05-08 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

支气管扩张患者下呼吸道细菌感染与定植研究初探

Public title:

Tentative Exploration of Bacterial Infection and Colonization in the Lower Respiratory Tract of Patients with Bronchiectasis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

西南地区支气管扩张患者责任感染菌感染与定植研究

Scientific title:

Infection and Colonization of Pathogen in Patients with Bronchiectasis in Southwest Area

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张剑青 

研究负责人:

张剑青 

Applicant:

Zhang Jianqing 

Study leader:

Zhang Jianqing 

申请注册联系人电话:

Applicant telephone:

+86 18988272502

研究负责人电话:

Study leader's
telephone:

+86 18988272502

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

ydyyzjq@163.com

研究负责人电子邮件:

Study leader's E-mail:

ydyyzjq@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

云南省昆明市西昌路295号

研究负责人通讯地址:

云南省昆明市西昌路295号

Applicant address:

295 Xichang Road, Kunming, Yunnan, China

Study leader's address:

295 Xichang Road, Kunming, Yunnan, China

申请注册联系人邮政编码:

Applicant postcode:

650000

研究负责人邮政编码:

Study leader's postcode:

650000

申请人所在单位:

昆明医科大学第一附属医院

Applicant's institution:

The First Affiliated Hospital of Kunming Medical University

研究负责人所在单位:

昆明医科大学第一附属医院

Affiliation of the Leader:

The First Affiliated Hospital of Kunming Medical University

是否获伦理委员会批准:

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

昆明医科大学第一附属医院呼吸与危重症2病区

Primary sponsor:

Department 2 of Pulmonary and Critical Care Medicine of the First Affiliated Hospital of Kunming medical University

研究实施负责(组长)单位地址:

云南省昆明市西昌路295号

Primary sponsor's address:

295 Xichang Road, Kunming, Yunnan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

云南

市(区县):

昆明

Country:

China

Province:

Yunnan

City:

Kunming

单位(医院):

昆明医科大学第一附属医院

具体地址:

西昌路295号

Institution
hospital:

The First Affiliated Hospital of Kunming Medical University

Address:

295 Xichang Road

国家:

中国

省(直辖市):

云南

市(区县):

昆明

Country:

China

Province:

Yunnan

City:

Kunming

单位(医院):

昆明医科大学第二附属医院

具体地址:

滇缅大道374号

Institution
hospital:

The Second Affiliated Hospital of Kunming Medical University

Address:

374 Dianmian Avenue

国家:

中国

省(直辖市):

云南

市(区县):

昆明

Country:

China

Province:

Yunnan

City:

Kunming

单位(医院):

解放军联勤保障部队920医院

具体地址:

大观路212号

Institution
hospital:

920th Haspital of the Joint Service Support Force of the PLA

Address:

212 Daguan Road

国家:

中国

省(直辖市):

云南

市(区县):

昆明

Country:

China

Province:

Yunnan

City:

Kunming

单位(医院):

昆明市第一人民医院

具体地址:

盘龙区北京路1228号

Institution
hospital:

The First Hospital of Kunming

Address:

1228 Beijing Road, Panlong District

国家:

中国

省(直辖市):

云南

市(区县):

昆明

Country:

China

Province:

Yunnan

City:

Kunming

单位(医院):

昆明市第一人民医院甘美医院

具体地址:

青年路504号

Institution
hospital:

Galmette Hospital and the First Hospital of Kunming

Address:

404 Qingnian Road

国家:

中国

省(直辖市):

云南

市(区县):

昆明

Country:

China

Province:

Yunnan

City:

Kunming

单位(医院):

云南省第二人民医院

具体地址:

五华区青年路176号

Institution
hospital:

The Second People's Hospital of Yunnan Procince

Address:

176 Qingnian Road, Wuhua District

国家:

中国

省(直辖市):

云南

市(区县):

昆明

Country:

China

Province:

Yunnan

City:

Kunming

单位(医院):

云南省第一人民医院

具体地址:

西山区金碧路157号

Institution
hospital:

The First People's Hospital of Yunnan Province

Address:

157 Jinbi Road, Xishan District

国家:

中国

省(直辖市):

云南

市(区县):

昆明

Country:

China

Province:

Yunnan

City:

Kunming

单位(医院):

云南省第三人民医院

具体地址:

北京路292号

Institution
hospital:

The Third People's Hospital of Yunnan Province

Address:

292 Beijing Road

国家:

中国

省(直辖市):

云南

市(区县):

昆明

Country:

China

Province:

Yunnan

City:

Kunming

单位(医院):

昆明市延安医院

具体地址:

盘龙区人民东路245号

Institution
hospital:

Yan’an Hospital of Kunming City

Address:

245 Renmin Road East, Panlong District

国家:

中国

省(直辖市):

云南

市(区县):

红河

Country:

China

Province:

Yunnan

City:

Honghe

单位(医院):

云南省滇南中心医院

具体地址:

个旧市金湖南路17号

Institution
hospital:

Southern Central Hospital of Yunnan Province

Address:

17 Jinhu Road South, Gejiu

国家:

中国

省(直辖市):

云南

市(区县):

西双版纳州景洪市

Country:

China

Province:

Yunnan

City:

Jinghong, Xishuangbanna Prefecture

单位(医院):

西双版纳傣族自治州人民医院

具体地址:

嘎兰南路4号

Institution
hospital:

The People's Hospital of the Xishuangbanna Dai Autonomous Prefecture

Address:

4 Galan Road South

国家:

中国

省(直辖市):

云南

市(区县):

楚雄

Country:

China

Province:

Yunnan

City:

Chuxiong

单位(医院):

楚雄彝族自治州人民医院

具体地址:

中大街278号

Institution
hospital:

The People's Hospital of Chuxiong Yi Autonomous Prefecture

Address:

278 Zhongda Street

经费或物资来源:

云南省“万人计划”云岭名医

Source(s) of funding:

Yunling ten thousand plan famous doctor in yunnan province

研究疾病:

支气管扩张症  

Target disease:

Bronchiectasis

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

析因分组(即根据危险因素或暴露因素分组) 

Study design:

Factorial 

研究目的:

1. 建立支气管扩张队列人群,分析西南地区支气管扩张患者感染病原分布。 2. 对照组为肺部小结节且排外感染者,支气管扩张患者为试验组,入组受试对象痰培养阳性者,根据临床判定分为定植组与感染组,采用mNGS技术探索感染与定植不同状态下,患者肺部微生态分布差异,并分析患者外周血/BALF宿主宏转录组表达差异。同时患者外周血/BALF行代谢组学检测,明确机体在感染或定植状态下的炎症反应代谢状态是否不同。AI影像组学分析感染和定植不同状态下的影像学差异。 3.痰培养结果提示铜绿假单胞菌者,分析感染组与定植组BALF铜绿假单胞菌宏转录组表达差异。  

Objectives of Study:

1.Estabolish a bronchiectasis cohort to analysis the pathogen distribution of patients with bronchiectasis in the southwest of China, 2.Control group is comprised by small pulmonary nodules and excluded infection. Trial group consist of patients with bronchiectasis. All of the subjects are positive sputum culture. According to clinical judgement divide trial group into infection group and colonization group. Metagenomic next-generation(mNGS) identify pulmonary microecological diversity under different conditions of infection and colonization, as well as analysis host macro transcriptome of patients blood and bronchoalveolar lavage fluid(BALF). Meanwhile, patient's peripheral blood and BALF are used for metabolome detection to identify the difference metabolic status between infection and colonization. Artificial intelligence(AI) Image Omics to analysis the imaging difference between infection and colonization. 3.To analysis BALF Pseudomonas aeruginosa(PA) bacterial macro transcriptomics of patients with PA positive sputum culture in infection group and colonization group.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

健康对照组纳入标准:1. 年龄:18-65岁;2. 胸部CT发现肺部结节。
试验组纳入标准:1. 年龄:18-80岁,经HRCT诊断为支气管扩张;2. 无论感染或定植需痰培养阳性,同时BALF经mNGS验证培养结果。

Inclusion criteria

Inclusion criteria of healthy control group:
1. Age: 18-65 years old;
2. Objects with pulmonary nodules found by chest CT.
Inclusion criteria of the test group:
1. Age: 18-80 years old, diagnosed as bronchiectasis by HRCT;
2. Whether infection or colonization requires sputum culture, BALF culture results were verified by mngs.

排除标准:

健康对照组排除标准:
① 近 4 周内出现急性感染的迹象,包括化脓性痰,高热或白细胞增多;
② 近4 周内有抗生素治疗史;
③ 合并其他慢性呼吸系统疾病;
④ 合并其他系统严重疾病;
⑤ 哺乳或怀孕期;
⑥ 近1月曾因其他肺部疾病入院治疗;中性粒细胞减少症;
⑦ 近1月使用长期免疫抑制剂者(使用激素时间>7天)
⑧ 不能耐受支气管镜;
⑨ 不签署知情同意书;

试验组排除标准:
① 合并其他慢性呼吸系统疾病;
② 合并其他系统严重疾病;
③ 哺乳或怀孕期;
④ 近1月曾因其他肺部疾病入院治疗;
⑤ 近4 周内有抗生素治疗史;
⑥ 中性粒细胞减少症;
⑦ 近1月使用长期免疫抑制剂者(使用激素时间>7天);
⑧ 不能耐受支气管镜;
⑨ 不签署知情同意书。

Exclusion criteria:

Exclusion criteria of healthy control group:
1. There were signs of acute infection in recent 4 weeks, including suppurative sputum, high fever or leukocytosis;
2. Antibiotic treatment history in recent 4 weeks;
3. Other chronic respiratory diseases;
4. Other serious diseases of the system;
5. Lactation or pregnancy;
6. He was admitted to hospital for treatment of other lung diseases in recent 1 month; neutropenia;
7. Those who used long-term immunosuppressive agents in the past 1 month (hormone use time > 7 days)
8. Subjects who could not tolerate bronchoscopy;
9. Subjects who did not sign informed consent.

Exclusion criteria of test group:
1. Other chronic respiratory diseases;
2. Other serious diseases of the system;
3. Lactation or pregnancy;
4. He was admitted to hospital for treatment of other lung diseases in recent 1 month;
5. There was a history of antibiotic treatment in the past 4 weeks;
6. Neutropenia;
7. Those who used long-term immunosuppressive agents in the past 1 month (hormone use time > 7 days);
8. Patients who can not tolerate bronchoscopy;
9. Patients who do not sign informed consent.

研究实施时间:

Study execute time:

From 2020-05-10 00:00:00 To 2021-05-10 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-05-10 00:00:00 To 2021-05-10 00:00:00

干预措施:

Interventions:

组别:

肺部结节组

样本量:

50

Group:

pulmonary nodule group

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

组别:

支气管扩张组

样本量:

55

Group:

bronchiectasis group

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

云南 

市(区县):

 

Country:

China

Province:

yunnan

City:

单位(医院):

昆明医科大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Kunming Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

云南 

市(区县):

 

Country:

China

Province:

Yunnan

City:

单位(医院):

昆明医科大学第二附属医院 

单位级别:

三级甲等 

Institution
hospital:

The Second Affiliated Hospital of Kunming Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

云南 

市(区县):

 

Country:

China

Province:

Yunnan

City:

单位(医院):

解放军联勤保障部队920医院 

单位级别:

三级甲等 

Institution
hospital:

920th Haspital of the Joint Service Support Force of the PLA

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

云南 

市(区县):

 

Country:

China

Province:

Yunnan

City:

单位(医院):

云南省第一人民医院 

单位级别:

三级甲等 

Institution
hospital:

The First People's Hospital of Yunnan Province

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

云南 

市(区县):

 

Country:

China

Province:

Yunnan

City:

单位(医院):

云南省第二人民医院 

单位级别:

三级甲等 

Institution
hospital:

The Second People's Hospital of Yunnan Province

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

云南 

市(区县):

 

Country:

China

Province:

Yunnan

City:

单位(医院):

云南省第三人民医院 

单位级别:

三级甲等 

Institution
hospital:

The Third People's Hospital of Yunnan Province

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

云南 

市(区县):

 

Country:

China

Province:

Yunnan

City:

单位(医院):

昆明市第一人民医院 

单位级别:

三级甲等 

Institution
hospital:

The First Hospital of Kunming

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

云南 

市(区县):

 

Country:

China

Province:

Yunnan

City:

单位(医院):

昆明市第一人民医院甘美医院 

单位级别:

三级甲等 

Institution
hospital:

Galmette Hospital and the First Hospital of Kunming

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

云南 

市(区县):

 

Country:

China

Province:

Yunnan

City:

单位(医院):

昆明市延安医院 

单位级别:

三级甲等 

Institution
hospital:

Yan'an Hospital of Kunming City

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

云南 

市(区县):

 

Country:

China

Province:

Yunnan

City:

单位(医院):

云南省滇南中心医院 

单位级别:

三级甲等 

Institution
hospital:

Southern Central Hospital of yunnan province

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

云南 

市(区县):

 

Country:

China

Province:

Yunnan

City:

单位(医院):

西双版纳傣族自治州人民医院 

单位级别:

三级甲等 

Institution
hospital:

The People's Hospital of the Xishuangbanna Dai Autonomous Prefecture

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

云南 

市(区县):

 

Country:

China

Province:

Yunnan

City:

单位(医院):

楚雄彝族自治州人民医院 

单位级别:

三级甲等 

Institution
hospital:

The People's Hospital of Chuxiong Yi Autonomous Prefecture

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

宏基因组二代测序

指标类型:

主要指标

Outcome:

metagenomics next-generation sequencing

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

微生物组学

指标类型:

主要指标

Outcome:

microbiome

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

转录组学

指标类型:

主要指标

Outcome:

transcriptomics

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

代谢组学

指标类型:

主要指标

Outcome:

metabolomics

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

降钙素原

指标类型:

次要指标

Outcome:

procalcitonin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

C反应蛋白

指标类型:

次要指标

Outcome:

C-reactive protein

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白细胞计数

指标类型:

次要指标

Outcome:

white blood cell count

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白介素-6

指标类型:

次要指标

Outcome:

interleukin-6

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白介素-8

指标类型:

次要指标

Outcome:

interleukin-8

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肿瘤坏死因子-α

指标类型:

次要指标

Outcome:

tumor necrosis factor-α

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

病原学检测

指标类型:

次要指标

Outcome:

etiological examination

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

T淋巴细胞亚群计数

指标类型:

次要指标

Outcome:

T-lymphocyte subsets analysis

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

AI影像组学

指标类型:

主要指标

Outcome:

artificial intelligence image omics

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

肺泡灌洗液

组织:

Sample Name:

bronchoalveolar lavage

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

组织:

Sample Name:

sputum

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究为观察性研究,不涉及随机分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

This rearch is an observation study,so there's no random grouping involved.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

本试验产生的血液及肺泡灌洗液的转录组学,代谢组学,肺泡灌洗液宏基因组二代测序结果,以及其他结果,都将在试验完成后6个月内上传至临床研究电子管理公共平台(Research Manager,ResMan)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

BALFand blood transcriptome、 matabolome、metagenomics next-generation sequencing ,and other results of this study will be loaded to the Research Manager(Resman) within six months after the trial comple

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

受试者样本采集由昆明医科大学第一附属医院呼吸科执行,血液及肺泡灌洗液的转录组、微生态及病原菌鉴定由广州微远基因科技有限公司检测,血液及肺泡灌洗液代谢组学由广州代谢组由上海厚基生物科技有限公司检测,源数据保存至负责人张剑青处,试验者样本信息录入由各中心采集和核对,并填写病例记录表,然后寄送至负责人张剑青处。张剑青保存所有的源数据,并上传至ResMan网站,并通过该网站进行管理。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Subjects'specimen collection are implemented by the Department of Respiratory and Critical Care medicine of the First Affiliated Hospital of Kunming Medical University.Transcriptome sequencing、microecological diversity and pathogen detection of blood and BALF are detected by Guangzhou Weiyuan Gene Technology co.LTD .Shanghai Houji biotechnology co.LTD test the metabolome. Each center collects and verifies the specimen information record of all of the subjects and finish the CRF,then send to the research leader, ZhangJianqing.Zhang preserve all of the source datas, upload to ResMan website,and manage datas by it。

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2020-05-08 18:31:48